Lack of Efficacy of Suvorexant in People With Insomnia and Poorly Controlled Type 2 Diabetes
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752032/
Sleep disturbance is a common and underappreciated feature of diabetes and sleep may contribute to glycemic control in people with type 2 diabetes (T2D). We conducted a 3-month trial to...
In this study of people with chronic insomnia and suboptimally controlled type 2 diabetes, the authors did not find evidence that suvorexant is effective in improving sleep over a 12-week period.
ADHD in Narcolepsy: a Closer Look at Prevalence and Ties
Source : https://www.sciencedirect.com/science/article/abs/pii/S0149763423004402?via=ihub
The reported prevalence of attention deficit hyperactivity disorder (ADHD) in narcolepsy varies considerably, while the associated factors remain inad...
This meta-analysis of 4 studies with healthy control groups showed that the OR for ADHD in patients with narcolepsy was approximately 10 times higher compared with healthy controls.
Are Some Children Genetically Predisposed to Poor Sleep? A Polygenic Risk Study in the General Population
Source : https://pubmed.ncbi.nlm.nih.gov/37936537/
Children who are genetically predisposed to insomnia have more insomnia-like sleep problems, whereas those who are genetically predisposed to longer sleep have longer sleep duration, but are also more awake...
Study researchers provided indirect evidence for a persistency of the “poor sleeper” phenotype across the lifetime, opening up the opportunity to design and conduct further research on genetically informed early detection and prevention of sleep problems.
A Novel Intervention to Simultaneously Address the Dual Pathologies of Breathing Disorders During Sleep and Undiagnosed Attention Deficit Hyperactivity Disorder in School-Aged Children Ages 5-12
Source : https://pubmed.ncbi.nlm.nih.gov/38031843/
Treatment with an MOA may be highly effective in addressing the dual pathologies of SDB and ADHD in school-age children ages 5 to 12.
Although there was a reduction of the overall average symptom score from the initial visit to 2 to 6 months, a statistically significant improvement in ADHD symptoms occurred at the 7+ month endpoint during MOA treatment.
Psychometric Evaluation of the PROMIS SD-SF-8b Instrument in Individuals Experiencing Vasomotor Symptoms Due to Menopause
Source : https://pubmed.ncbi.nlm.nih.gov/37990323/
ClinicalTrials.gov numbers: NCT04003155 and NCT04003142.
A PROMIS SD-SF-8b total score of 8 points was identified as the within-patient threshold to use to confirm a meaningful change in sleep disturbance.